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Objectives. Our aim was to determine whether vascular deposition of advanced glycation end-products (AGEs) is associated with
arterial calcification and cardiovascular mortality in chronic kidney disease (CKD) patients and to assess the relationships between
vascular content of AGEs and selected clinical and biochemical parameters.Materials and Methods.The study comprised 54 CKD
patients (33 hemodialyzed, 21 predialyzed). Examined parameters included BMI, incidence of diabetes, plasma fasting glucose,
AGEs, soluble receptor for AGEs and 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging, serum C-reactive protein (hsCRP),
plasminogen activator inhibitor-1 (PAI-1), and fetuin-A. Fragments of radial artery obtained during creation of hemodialysis access
were stained for calcifications using alizarin red. AGEs deposits were identified immunohistochemically and their relative content
was quantified.Results.Vascular content of AGEswas positively correlatedwith BMI, hsCRP, fetuin-A, PAI-1, andDPPH scavenging
in simple regression; only fetuin-Awas an independent predictor inmultiple regression.There was a significant positive trend in the
intensity of AGEs immunostaining among patients with grades 1, 2, and 3 calcifications. AGEs immunostaining intensity predicted
3-year cardiovascular mortality irrespective of patient’s age. Conclusions.The present study demonstrates an involvement of AGEs
in the development of medial arterial calcification and the impact of arterial AGE deposition on cardiovascular mortality in CKD
patients.
1. Introduction
Advanced glycation end-products (AGEs) and their receptor
play an important role in the pathogenesis of vascular damage
and cardiovascular disorders, especially in patients with dia-
betes and chronic kidney disease (CKD). AGEs accumulate
in various organs of the body including the heart and large
blood vessels, leading to accelerated plaque formation as
well as increased cardiac fibrosis with consequent effects on
cardiac dysfunction. Medial arterial calcification (MAC) has
been shown to increase the accumulation of AGEs on elastin
and collagen in the aorta of patients and in femoral arteries
in animal model [1]. Elastin stiffening induced by AGE
cross-links appeared in parallel with an increase in calcium
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uptake by elastin. The calcium binding was also increased in
collagen exposed to glucose. It was found that diabetic serum
induced a receptor for advanced glycation end-products-
(RAGE-) dependent calcification of vascular smooth muscle
cells (VSMCs). AGEs not only enhance the affinity of the
extracellular matrix components for calcium but also induce
signaling pathways, resulting in cell phenotype changes.
RAGE activation caused the osteogenic differentiation of
VSMC by the activation of the extracellular-signal-regulated
kinases 1/2 (ERK1/2) pathways [2].
The initial accumulation of AGEs in the vascular tissue
could exacerbate local inflammation and lead to downstream
cellular activities that favor cell-mediated vascular calcifica-
tion by activation of RAGE [3, 4]. Ren et al. [3] demonstrated
that, in response to AGEs, rat aortic VSMCs differentiate into
cells that exhibit an osteoblast-like phenotype, characterized
by the deposition of calcium in the extracellular matrix and
the expression of genes normally restricted to mineralized
tissues, such as osteopontin and alkaline phosphatase. RAGE
has emerged as a central regulator of vascular inflammation
and atherosclerosis. Soluble RAGE (sRAGE) has an anti-
inflammatory effect by quenching ligands for RAGE.The cir-
culating sRAGE level was inversely associated with vascular
calcification scores in hemodialyzed patients irrespective of
the severity of systemic inflammation [5].
The aim of the present study was to determine whether
AGE content in the arterial wall, as expressed by the intensity
of immunostaining, is significantly associated with histo-
logically assessed arterial calcification and the incidence of
cardiovascular events in patients with stage 5 chronic kidney
disease. Moreover, we examined possible correlations of
vascular AGEs deposits and calcifications with the levels of
circulating AGEs and sRAGE as well as markers of bone and
mineral metabolism, inflammation, and oxidative stress.
2. Materials and Methods
2.1. Patients. The study population consisted of 54 patients
(stage 5 of CKD), including 33 on maintenance hemodialysis
(HD) and 21 on predialysis. The study included patients
who underwent the first creation of arteriovenous fistula for
hemodialysis access. The majority of the subjects were men
(34, i.e., 63%). The mean age at the beginning of the study
was 61 ± 16 years. The mean arterial pressure (MAP) was
calculated according to the formula: MAP = (SBP + 2 ×
DBP)/3, where SBP = systolic blood pressure and DBP =
diastolic blood pressure.
The data onmortality was collected over a period of three
years. All deaths occurred in hospital and causes of death
were determined using history documentation.
The study was approved by the Bioethics Committee
of the Jagiellonian University and all patients signed an
informed consent for their participation.
2.2. Laboratory Tests. Blood samples of the patients were
obtained at the beginning of the study in the morning before
creation of arteriovenous fistula for hemodialysis access.
Serum samples for ELISA tests were aliquoted and stored at
−70∘C until being assayed (no longer than 3 months). Plasma
samples used to assess oxidative stress parameters were
protected from light, placed on ice and centrifuged within 2
hours after collection, then aliquoted, and stored at −30∘C
until analysis (no longer than one month). In all patients,
the following biochemical parameters were assessed: serum
concentrations of total cholesterol, HDL-cholesterol, LDL-
cholesterol, triglycerides (TG), serum creatinine, albumin,
glucose, parathyroid hormone (iPTH), total calcium (Ca)
and phosphate (Pi), advanced glycation products (AGEs), the
soluble form of receptor for advanced glycation end-products
(sRAGE), inflammatory markers, high sensitive C-reactive
protein (hsCRP), interleukin-6 (IL-6), plasminogen activator
inhibitor PAI-1 (PAI-1), and fetuin-A, and calcificationmark-
ers, osteopontin (OPN), osteoprotegerin (OPG), osteocalcin
(OC), and fibroblast growth factor 23 (FGF-23). Homeosta-
sis Model of Assessment-Insulin Resistance (HOMA-IR) was
calculated by application of the international formula: fasting
insulin (𝜇IU/mL) × fasting glucose (mmol/L)/22.5. The
estimated glomerular filtration rate (eGFR) was calculated
by Modification of Diet in Renal Disease (MDRD) formula:
eGFR = 186 × [serum creatinine (𝜇mol/L) × 0.0113]−1.154 ×
age−0.203 × (0.742 for women).
Routine biochemical tests were carried out using auto-
matic biochemical analyzers: Hitachi 917 (Hitachi, Japan) and
Modular P (Roche Diagnostics, Mannheim, Germany). Con-
centrations of hsCRP were measured using immunonephelo-
metricmethod andNephelometer BN II (SiemensHealthcare
Diagnostics, Germany).
Inflammatory and calcificationmarkers were determined
using ELISA microplate immunoassays and ELX808 auto-
matic reader (BioTEK Instruments Inc., Vermont, USA).The
following sets of kit reagents were applied: IL-6 (R&D Sys-
tems, Minneapolis, MN, USA), PAI-1 (Human Serpin/PAI-1,
R&D Systems, Minneapolis, MN, USA), fetuin-A (BioVen-
dor, Czech Republic), OPN (R&D Systems, Minneapo-
lis, MN, USA), OC (METRA, Germany), OPG (QUIDEL,
BioVendor, Czech Republic), and FGF-23 (C-Term) (Immu-
topics Inc., San Clemente, USA).
AGE and sRAGE concentrations were measured with
commercially available Human ELISA kits (BIOMATIK, Life
Science Products and Services, Canada) according to the
manufacturer’s protocol. Spectrophotometric measurements
were performed using microplate reader Polar Star Omega
(BMG Labtech, Germany). Total antioxidant capacity of
plasma was assessed as the ability of plasma to reduce Fe3+
to Fe2+ (ferric reducing ability of plasma—FRAP), according
to Benzie’smethod [6]. Radical scavenging capacity of plasma
was estimated byDPPH radical scavenging assay as described
elsewhere. Ferric reducing ability of ascorbate in plasma
(FRASC) was measured spectrophotometrically [6, 7].
2.3. Histology. Small fragments of radial artery wall, approx-
imately 5 × 2mm in size, were collected during the first
creation of arteriovenous fistula for hemodialysis access. The
samples were fixed overnight in 10% phosphate-buffered
formalin and then rinsed in PBS and soaked in 30%
sucrose. The material was snap-frozen and tissue blocks
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were positioned in a cryostat to allow cutting sections in
a longitudinal plane of the vessel encompassing the entire
thickness of the vascular wall. Serial 10 𝜇m thick cryosections
were cut and thaw-mounted on poly-L-lysine coated slides.
Sections were stained routinely with Mayer’s haematoxylin
and eosin (HE) for general morphology and with alizarin
red for calcifications. AGE deposits were detected using
indirect immunofluorescence labelling. Briefly, after preincu-
bation with 5% normal goat serum for 20min the sections
were incubated overnight with polyclonal rabbit anti-AGE
antibody (ab23722, Abcam, Cambridge, UK; 1 : 200). After
rinsing in PBS sections were incubated with secondary Cy3-
conjugated goat anti-rabbit serum (111-165-164, Jackson IR,
West Grove, PA; 1 : 400) for 1 h and then rinsed and mounted
in glycerin/PBS. To verify specificity of the immunostaining
control reactions omitting primary antibody and/or sec-
ondary antiserum were applied.
Sections were examined under Olympus BX-50 micro-
scope (Olympus, Tokyo, Japan) in brightfield mode for histo-
logical staining and in fluorescence mode for immunolabel-
ing. Images were acquired using Olympus DP-71 digital CCD
camera controlled by Olympus AnalySIS FIVE software. All
images from immunolabeled sections were recorded under
standardized conditions of the fluorescent lamp (identical
power of the excitation light) and of the camera (sensi-
tivity and acquisition time). The advancement of vascular
calcification was semiquantitatively assessed in alizarin red-
stained sections by two independent observers.The degree of
mineralizationwas classified according to the following scale:
0, no mineral content; 1, a few small dispersed concretions;
2, numerous small dispersed concretions; 3, larger granular
concretions; and 4, large areas occupied by fused mineral
deposits. AGE depositionwas quantified in the arterial media
by measuring mean red fluorescence intensity (range 0–
255, arbitrary units) in the analyzed area and expressed as
the mean fluorescence intensity for each vessel. From each
sample three sections fromdifferent depths of the tissue block
were analyzed. The appropriate algorithms for quantification
were adopted in AnalySIS FIVE software.
The reproducibility of the morphological analysis was
confirmed by Bland-Altman method and by calculating
intraclass correlation coefficient (ICC) which was 0.88.
2.4. StatisticalMethods. Thedata are expressed as the number
of patients (percentage of the particular group) for categories
and as mean ± SD or median (lower-upper quartile) for
continuous variables, according to the distribution. Shapiro-
Wilk test was used to check for normality. Contingency
tables were analyzed with Pearson chi-squared test. Stu-
dent’s 𝑡-test or Mann-Whitney test was used for simple
comparisons between the groups. Simple and multiple linear
regressions were calculated after log-transformation of right-
skewed variables. Multiple regression included the predictors
significantly correlated with dependent variable in simple
regression (𝑃 < 0.05). Variance inflation factors (VIF) were
calculated for the predictor variables; VIF above 5 were not
accepted.The association between the intensity of immunos-
taining for AGEs and the degree of vascular calcification was
tested with one-way ANOVA and trend analysis. Logistic
regression analysis was used to study the associations with
mortality; odds ratio (OR) for 1 SD increment was reported
with 95% confidence interval (95% CI). All tests were two-
tailed and the results were considered significant at 𝑃 ≤ 0.05.
The computationswere performedusing Statistica 10 software
(StatSoft, Tulsa, OK, USA).
3. Results
3.1. Characteristics of the Study Group. Clinical characteris-
tics of the patients and the results of the laboratory tests are
presented in Table 1.
According to the results of AGE immunostaining mea-
surements, the patients were divided into two groups: those
showing the vascular AGE content above and below the
median value (48.3). Patients with high content of AGEs in
radial artery had higher concentrations of fetuin-A and PAI-1
as well as higher free radical scavenging capacity of plasma
(as shown by DPPH scavenging assay).
The AGE content in radial artery did not differ between
the diabetics and nondiabetics (54.9 (42.2–85.9) versus 45.9
(30.5–72.1); 𝑃 = 0.2) and did not depend on hemodialysis
status (HD versus predialysis: 57.0 (33.0–81.8) versus 42.8
(34.6–60.9); 𝑃 = 0.3). Similarly, serum concentrations of
AGEs and sRAGE as well as the ratio of AGEs/sRAGE did
not differ significantly between patients with and without
diabetes or between dialyzed and predialyzed subjects.
3.2. Histological Findings. Calcifications of various grades
were detected in radial artery samples of 30 patients (56%):
11 patients had grade 1, 5 grade 2, 8 grade 3, and 6 grade 4
calcifications.
AGE immunohistochemistry showed intense reaction in
the intima and in the adventitia of the examined vessels.
In the media, AGE deposits were seen in various grades of
advancement and they were mostly localized extracellularly
between smooth muscle cells (Figures 1(c) and 1(d)). Since
the immunostaining in intima and adventitiamay result from
nonspecific binding of AGE antibodies to glycoproteins (e.g.,
collagen), only AGEs located in the media were considered
for further measurements and comparisons.
3.3. Correlations of AGE Content in Radial Artery with
Clinical and Biochemical Parameters. The intensity of AGEs
staining in radial arteries of stage 5 CKD patients positively
correlated with BMI, hsCRP, fetuin-A, PAI-1 concentrations,
and DPPH scavenging (Table 2; right-skewed variables were
log-transformed). Neither AGEs, sRAGE, nor AGEs/sRAGE
ratio correlated with the intensity of radial artery staining
for AGEs. In multiple regression, only fetuin-A predicted the
intensity of AGEs staining in radial artery wall independently
of log (BMI), log (hsCRP), log (PAI-1), and log (DPPH
scavenging) (Table 2). Variance inflation factors (VIF) for the
predictor variables were <2.
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Table 1: Clinical and laboratory characteristics of stage 5 CKD patients at the start of the study.
Intensity of AGEs staining >median
(𝑁 = 27)
Intensity of AGEs staining ≤median
(𝑁 = 27) 𝑃
Age, years 63.1 ± 14.9 59.2 ± 17.2 0.4
Male gender,𝑁 (%) 18 (67) 16 (59) 0.6
Hemodialyzed, 𝑁 (%) 19 (70) 14 (52) 0.2
Dialysis duration, monthsa 7 (2–32) 11 (2–38) 0.7
BMI, kg/m2 27.5 ± 6.1 25.1 ± 5.4 0.067
Diabetes,𝑁 (%) 9 (33) 7 (26) 0.6
Active smoking,𝑁 (%) 10 (37) 6 (22) 0.2
Hypertension,𝑁 (%) 11 (41) 11 (41) 1.0
MAP, mmHg 102 ± 12 103 ± 13 0.6
Serum creatinine, 𝜇mol/L 464 (405–596) 446 (313–510) 0.1
eGFR (MDRD), mL/min/1.73m2a 12 (10–14) 14 (10–19) 0.4
Albumin, g/L 41.7 ± 3.4 40.1 ± 6.0 0.4
Total cholesterol, mmol/L 4.65 ± 1.27 4.97 ± 1.76 0.6
HDL-cholesterol, mmol/L 1.23 ± 0.38 1.30 ± 0.40 0.6
LDL-cholesterol, mmol/L 2.56 ± 1.00 2.70 ± 1.41 0.8
Triglycerides, mmol/L 1.98 ± 1.17 2.10 ± 1.00 0.4
Fasting glucose, mmol/L 5.30 (4.80–7.90) 5.00 (4.40–5.40) 0.2
Insulin, 𝜇U/mLb 10.7 (6.2–23.8) 8.4 (5.2–12.1) 0.3
HOMA-IRb 2.28 (1.32–4.85) 1.68 (1.08–2.68) 0.2
Ca × Pi, mmol2/L2 3.59 (2.87–4.46) 3.04 (2.91–3.70) 0.4
iPTH, pg/mL 286 (186–524) 265 (153–343) 0.4
OPN, ng/mL 340 (225–681) 315 (215–438) 0.3
OPG, pmol/L 7.80 (5.76–10.61) 7.43 (3.03–12.52) 0.5
OC, ng/mL 44.2 (33.6–78.2) 41.8 (24.6–61.8) 0.2
FGF-23, RU/mL 1148 (487–5066) 970 (435–1468) 0.3
Fetuin-A, g/L 0.27 ± 0.06 0.23 ± 0.04 0.042
CRP, mg/L 9.64 (2.97–19.00) 4.80 (2.19–17.90) 0.5
IL-6, pg/mL 4.58 (1.86–6.36) 3.89 (2.18–8.22) 0.7
uric acid, 349 (234–426) 355 (259–432) 0.9
FRAP, mM/L 0.75 (0.62–1.21) 0.74 (0.52–1.06) 0.5
FRASC, 𝜇M/L 46.8 (41.0–58.9) 50.2 (43.1–57.3) 0.9
DPPH, % 43.4 (37.4–68.0) 36.8 (33.0–40.5) 0.007
PAI-1, ng/mL 1.92 (1.58–2.57) 1.16 (0.95–1.77) 0.011
Plasma AGEs, ng/mL 537 (274–741) 492 (251–2570) 0.8
Plasma sRAGE, ng/mL 1.75 (1.09–2.73) 1.91 (1.32–2.72) 0.7
Plasma AGEs/sRAGE 412 (116–777) 264 (132–1455) 0.7
AGEs in radial artery, arbitrary units 80.9 ± 18.7 33.6 ± 9.5 —
aData for hemodialyzed patients; bdata for patients without diabetes.
3.4. Association of AGE Content in Radial Artery and AGEs,
sRAGE, and AGEs/sRAGE in Serum with Vascular Calcifi-
cation. We did not observe significant differences regarding
AGE and sRAGE serum concentrations, AGEs/sRAGE ratio,
or the intensity of vascular staining for AGEs between
patients with and without vascular calcifications. However,
there was a significant positive trend in the intensity of AGE
staining among patients with alizarin red staining grades 1, 2,
and 3 (one-way ANOVA: 𝐹
2,21
= 4.13;𝑃 = 0.031; 𝑃 for trend =
0.010; Figure 2).This trendwas also significant after excluding
diabetic patients from the analysis (𝑃 = 0.001).
3.5. Association of AGE Content in Radial Artery with Mor-
tality. During 3-year observation period, 15 (28%) patients
died, including 12 due to cardiovascular causes (myocardial
infarction in 5 cases, heart failure in 6, and cerebral stroke
in 1 patient). More deaths (11 versus 4; 𝑃 = 0.033),
including cardiovascular ones (10 versus 2; 𝑃 = 0.008),
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Figure 1: Consecutive sections of radial arteries stained with alizarin red (a, c, and e) and immunostained for AGE (b, d, and e) showing
calcifications of various grades 0 (a), 2 (c), and 4 (e). AGEdeposits immunolabeled in red color presenting low (b and f) and high (d) intensities
of the immunofluorescence in media. Bar = 200𝜇m.
Table 2: Predictors of AGE staining intensity in radial arteries in simple and multiple linear regressions.
Simple regression Multiple regression
𝑅 𝑃 Beta ± SE 𝑃
log(BMI) 0.27 0.047 0.16 ± 0.15 0.3
log(hsCRP) 0.29 0.045 0.22 ± 0.14 0.1
Fetuin-A 0.46 0.002 0.32 ± 0.15 0.045
log(PAI-1) 0.40 0.005 0.07 ± 0.16 0.7
log(DPPH scavenging) 0.36 0.014 0.22 ± 0.15 0.2
Whole model — 𝑅2 = 0.32; 𝑃 = 0.013
𝑅: correlation coefficient, SE: standard error, and 𝑅2: coefficient of determination.
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Figure 2: The association between alizarin red staining and AGE
immunostaining intensity in radial arteries of patients with nonmas-
sive vascular calcifications.
occurred in patients with high (i.e., above median) intensity
of vascular staining for AGEs (Figure 3). In logistic regression
analysis, the intensity of AGE staining significantly predicted
cardiovascular (not all-cause) mortality (OR 2.10 (1.04–4.26)
per 1 SD increment; 𝑃 = 0.030), irrespective of patient’s
age. There were no associations of plasma AGE and sRAGE
concentrations or AGEs/sRAGE ratio with overall and car-
diovascular mortality.
4. Discussion
To the best of our knowledge, this is the first report where
AGE content was measured using quantitative immuno-
chemistry in human tissues obtained intravitally. Using small
samples of radial artery obtained during the creation of arte-
riovenous fistula for hemodialysis access, we showed for the
first time the association between the intensity of AGE stain-
ing and the severity of medial arterial calcification (MAC)
in patients with renal failure. Earlier studies examining the
impact of AGEs on the calcification processes were carried
out primarily in diabetic patients or using animal experi-
mental models in vivo and in vitro [1, 8–14]. Furthermore,
earlier studies mainly focused on the associations of AGEs
with atherosclerosis in patients without CKD. Baumann
et al. [15] demonstrated that the advanced glycation end-
product N𝜀-carboxymethyllysine (CML) was present in the
subendothelial space, especially in the atheromatous lesions
of human carotid artery obtained during carotidectomy. In
contrast, our study demonstrated the presence of AGEs
deposits in the medial layer of human radial arteries. This is
the first study showing the presence of AGEs in this layer of
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Figure 3: All-cause (black bars) and cardiovascular (grey bars)
mortality rate in patients with high and low AGE content in radial
artery.
artery walls in living patients. Similarly, large and medium-
sized mineral deposits were found most frequently in the
vascular media.
MAC represents calcification that proceeds via matrix
vesicle-nucleatedmineralization accompanied by apatitic cal-
cium phosphate deposits in the arterial media in the absence
of atheroma. Osteoblast-like cells differentiate in the vessel
wall from vascular smooth muscle cells and multipotent
vascular mesenchymal progenitors. These cells, as well as the
recruitment of undifferentiated progenitors of the osteochon-
drocyte lineage, play a critical role in the calcification process
[16]. Transcription factors expressed by these cells such as
Msx 2, Osterix, and RUNX2 are crucial in the programming
of osteogenesis [2, 9]. However, most studies assessing the
risk of calcification use noninvasive methods, such as CT
scan and pulse wave velocity, without specifying the nature
of the changes in the vessel (i.e., atherosclerotic changes or
MAC). In particular, the data on the relationship between
AGEs, sRAGE levels, and calcification were collected on the
basis of such studies [17, 18].Multiple factors contribute to the
induction and progression of MAC, including inflammation,
oxidative stress, bone, andmineral disorders, as well as AGEs
in diabetic patients [8, 15, 19]. We observed the association
between AGE content in the medial layer of radial artery
with the degree of MAC in CKD patients. Importantly, the
association was significant after excluding subjects without
diabetes. Also, the intensity of staining forAGEs did not differ
between diabetics and nondiabetics.
Interestingly, we found no significant relationship
between plasma AGEs and sRAGE concentrations and the
content of AGEs in the media of radial arteries. We have
not found any studies on the relationship between plasma
AGEs and the magnitude of AGEs deposits in arterial wall.
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According to our results, accumulation of AGEs in the vessel
wall does not directly correlate with its concentration in
plasma. However, we used a nonselective ELISA method
detecting various types of AGEs; thus we cannot exclude that
only selected AGE types form arterial wall deposits.
BMI and parameters of inflammation and oxidative stress
are recognized as the factors associated with vascular calci-
fication [20, 21]. Our results showed a relationship between
hsCRP and the severity of AGE deposition in the medial
layer of the radial artery. The initial accumulation of AGEs
in vascular tissue could exacerbate local inflammation and
lead to downstream cellular events that favour cell-mediated
vascular calcification via activation of RAGE. On the other
hand, chronic inflammation may increase the calcification
processes in renal failure [22, 23]. Vascular reactive oxygen
species (ROS) contribute to vascular functional and struc-
tural alterations. High levels of ROS can result in the reduc-
tion of proliferation, increased apoptosis, and modulation of
differentiation. AGEs are able to quench nitric oxide (NO)
and increase the generation of ROS such as peroxynitrite [10].
Our study showed a relationship between DPPH scavenging
and the content of AGEs in the vessel wall. Studies using
animal models confirm this suggestion. In rat model of
diabetes that shared similarities with human type 2 diabetes,
calcification was induced by vitamin D3 and nicotine. The
authors showed a significant increase in aortic calcium
content, levels of aorta AGEs, malondialdehyde content, ALP
protein levels, and RAGE expression together with significant
decrease in Cu/Zn superoxide dismutase (SOD) activity [10].
SOD acts as the first line of defense against oxygen free
radical mediated damage by catalyzing the dismutation of
superoxide anions. Brodeur et al. [1] demonstrated that AGE
inhibitors prevent time-dependent accumulation of AGEs in
femoral arteries in diabetic rats. This effect was accompanied
by a reduction in diabetes-accelerated calcification. Ex vivo
experiments showed N-methylpyridinium as an agonist of
RAGE-mediated calcification of diabetic femoral arteries, a
process inhibited by antioxidants and various inhibitors of
signaling pathways associated with RAGE activation. The
importance of oxidative stress was demonstrated by the
reduction of femoral medial artery calcification in diabetic
rats treated with apocynin, an inhibitor of reactive oxygen
species production. Engagement of RAGE with AGEs elic-
its intracellular ROS generation and subsequently activates
mitogen-activated protein kinase and nuclear factor kappa-
B signaling, followed by production of several inflammatory
species and profibrotic factors such as vascular cell adhe-
sion molecule-1 (VCAM-1), intracellular adhesion molecule-
1 (ICAM-1), plasminogen activator inhibitor-1 (PAI-1), and
monocyte chemoattractant protein-1 (MCP-1), involved in
the progression of atherosclerosis [12]. We have shown a
relationship between the plasma levels of PAI-1 and the
intensity of immunostaining for AGEs in the media of radial
artery walls. However, the role of PAI-1 in the development of
MAC has not been elucidated.
Fetuin-A is a negative acute-phase protein, which acts as
a potent calcification inhibitor and an antagonist of TGF-
𝛽. Thus, fetuin-A serum concentrations are influenced by
chronic inflammation and actively affect fibrosis and calcifi-
cation processes. Several studies have shown that fetuin-A is
a potent inhibitor of calcifications both in vivo and in vitro
[24, 25]. In our study, fetuin-A was an independent predictor
for deposits of AGEs in radial artery walls. Roos et al. [26]
examined the correlation between FGF-23, fetuin-A, and
coronary artery calcium score in patients with normal renal
function. They found no correlation between the presence of
noncalcified plaques and coronary artery stenosis and serum
fetuin-A concentrations. However, correlations between low
fetuin-A levels and vascular or valvular calcifications in CKD
patients have been shown in several studies [27, 28]. Schlieper
et al. [29] performed ultrastructural analysis of iliac artery
segments of dialysis patients and observed an association
between microcalcifications in the media and local con-
tent of calcification inhibitors including fetuin-A. Similarly,
Maréchal et al. [30] demonstrated that low serum fetuin-
A concentrations were independently associated with aortic
calcifications and higher risk of CV events and mortality.
Our study showed a positive relationship between serum
level of fetuin-A and the intensity of staining for AGEs in
arterial media. Moreover, fetuin-A was the only independent
predictor of AGE content in the arterial media and since
that content was correlated with degree of calcification at
early stages ofMAC development, increase in fetuin-A serum
level seems to be associated with the initial progression
of arterial calcification. This result seems to contradict the
anticalcific activity of fetuin-A; however it can suggest a
possible protective upregulation of fetuin-A at the early stages
of exposure to the procalcific and proinflammatory uremic
environment.
In patients suffering from CKD, medial calcification
of peripheral arteries is a strong independent predictor of
cardiovascular morbidity and mortality [31–34]. Our study
showed for the first time that the intensity of AGE deposition
in arterialmedia significantly predicted not only the advance-
ment of medial arterial calcification but also cardiovascular
mortality in CKD patients. In the literature only a few reports
point to the relationship between the concentration of serum
AGEs and cardiovascular risk but there are no data on the
relationship between AGE deposits in blood vessels and
mortality [35, 36].
5. Conclusions
The present study demonstrates an involvement of AGEs
in the development of medial arterial calcification and the
impact of arterial AGE deposition on cardiovascular mortal-
ity in CKD patients.
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